Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Analysts fell to the sidelines weighing in on Revvity (RVTY – Research Report) and Intra-Cellular Therapies (ITCI – Research Report) with ...
Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback